Abstract
Post-COVID syndrome (PCS) has emerged as a significant health concern with persisting symptoms. A subset of PCS patients develops severe myalgic encephalomyelitis/chronic fatigue syndrome (pcME/CFS). Dysregulated autoantibodies (AABs) have been implicated in PCS, contributing to immune dysregulation, impairment of autonomous nerve and vascular function. As recently shown in autoimmune diseases, IgG fractions translate disease-specific pathways into various cells. Therefore, we asked whether IgG fractions from PCS patients could be applied in-vitro to identify specific cytokine responses for PCS patients without (nPCS) and with pcME/CSF. To assess this, we have stimulated monocyte cell lines with IgG fractions from PCS patients. Our findings reveal distinct cytokine responses induced by patient derived AABs which are suggested in vascular and immune dysfunction. In contrast to nPCS, pcME/CSF AABs induced enhanced neurotrophic responses, characterized by significant cytokine correlations involving brain-derived neurotrophic factor (BDNF), glial cell-derived neurotrophic factor (GDNF) and tumor necrosis factor superfamily member 14 (LIGHT). Further, AAB-induced cytokine levels correlate with clinical symptoms. This study emphasizes a contribution of AABs in PCS, in mitigating long-term immune dysregulation, and a need for therapies modulating IgG-induced signaling pathways.
Competing Interest Statement
The authors GR and AH hold a submitted patent for cytokine signature detecting Post-COVID Syndrome, signatures for Post-COVID Syndrome with or without ME/CFS, respectively. The authors declare that HH and KS-F are managing directors of CellTrend. The remaining authors declare that the research was conducted in the absence of any commercial or financialrelationships that could be construed as a potential conflict of interest.
Funding Statement
Founded by BMBF (German ministry for education and research) project: Elucidating the immune pathomechanisms of post-infectious ME/CFS (IMMME), funding number 01EJ2204C.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the Ethics Committee of Charité Universitä;tsmedizin Berlin (EA2/067/20, EA2/066/20).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.